Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

51.02 +0.46 (+0.92%)
Streaming Delayed Price Updated: 12:54 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
43 44 Next >
News headline image
Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock? ↗
This vaccine candidate could help tackle the respiratory syncytial virus. 
Via The Motley Fool
News headline image
March 2023 Stock Considerations ↗
The calendar has turned, and a new trading month is upon us. 2023 is flying by as two months are already in the books, and that fact simply highlights the importance of staying invested in the stock... 
Via Talk Markets
News headline image
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK's Candidate Soon After Pfizer's ↗
 
Via Benzinga
News headline image
3 Crucial Things to Know About Moderna Right Now ↗
This vaccine leader is preparing for a post-pandemic world. 
Via The Motley Fool
News headline image
GSK's Relief For Few Months, First Trial Claiming Zantac Caused Cancer Pushed Into Late 2023 ↗
The first scheduled trial expected next week, related to GSK Plc's (NYSE: GSK) Zantac associated with cancer, has been postponed, likely by several months. 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields ↗
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
News headline image
GSK CEO Emma Walmsley On Beating Q4 Earnings ↗
GSK came out with quarterly earnings of $0.64 per share. 
Via Talk Markets
News headline image
GSK Posts Higher Q4 Sales, Profits, With Record Sales From Shingles Vaccine ↗
 
Via Benzinga
News headline image
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows ↗
 
Via Benzinga
News headline image
Intel and 9 Other Companies With Dividend Cuts in 2023 ↗
Intel announced that it would cut its dividend by a whopping 66%. Here are nine other companies that have also seen dividend cuts this year. 
Via InvestorPlace
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Preview: GlaxoSmithKline's Earnings ↗
 
Via Benzinga
News headline image
My 3 Biggest Stock Market Predictions for March ↗
These three trends will likely drive revenue and share prices. 
Via The Motley Fool
News headline image
EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue ↗
Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among... 
Via Benzinga
News headline image
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals ↗
 
Via Benzinga
News headline image
Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out ↗
Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.  
Via Benzinga
News headline image
Dividend Income Update For January 2023 ↗
Without rehashing the wild ride we experienced in the market over the last few months, I could find comfort in one thing: my dividends (even if dividend cuts are on the table these days). Let's see how... 
Via Talk Markets
News headline image
Week In Review: CANbridge In-Licenses Gene Therapy For Rare Disease From UMass ↗
CANbridge Pharma exercised an option for global rights to a novel second-gen gene therapy from UMass Chan medical school. Additionally, Zhimeng Biopharma signed an agreement to out-license global... 
Via Talk Markets
News headline image
FDA AdComm Votes In Favor Of GSK's Jemperli Single Arm Trial Plan For Rectal Cancer Setting ↗
 
Via Benzinga
News headline image
FDA Grants Complete Approval For GSK's Jemperli For Endometrial Cancer ↗
 
Via Benzinga
News headline image
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
News headline image
February 2023 Stock Considerations ↗
With a new trading month already in full swing, it is time to highlight some of my potential stock purchases. While the market had a nice bounce in recent months, there is still no shortage of stocks... 
Via Talk Markets
News headline image
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review ↗
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
News headline image
FDA Approves First Oral Treatment For Anemia Due To Chronic Kidney Disease ↗
 
Via Benzinga
News headline image
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report ↗
Two of the three companies easily beat sales and earnings expectations, but sales fell for the third. 
Via Investor's Business Daily
News headline image
Earnings Scheduled For February 1, 2023 ↗
Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion. 
Via Benzinga
News headline image
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
News headline image
CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs ↗
 
Via Benzinga
News headline image
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK ↗
But Moderna stock didn't move higher on the announcement. 
Via Investor's Business Daily
News headline image
How Could GSK's RSV Vaccine Change its Valuation?
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future. 
Via MarketBeat
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
43 44 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.